Pasithea Therapeutics, a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, filed its registration statement on Form S-1 for a proposed $24.0 million IPO.
On Wednesday, the company announced the pricing of its initial public offering of 4.8 million units, with each unit consisting of one share of common stock, at a public offering price of $5.00 per Unit.
Why It Matters
“Today’s announcement is a monumental achievement for Pasithea. Our successful IPO is testament to our work as a biotech company paving the way for new solutions to address how we treat mental health disorders,” Dr. Tiago Reis Marques, CEO and director of Pasithea Therapeutics Corp told …